Peter Batar
Hussain Alizadeh2- 1Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 21st Department of Medicine, Division of Haematology, Clinical Center, Medical School, University of Pecs, Pecs, Hungary
- 3RxTarget Ltd., Szolnok, Hungary
- 4Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary
- 5Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
by Batar P, Alizadeh H, Rokszin G, Abonyi-Toth Z and Demeter J (2024). Pathol. Oncol. Res. 30:1611497. doi: 10.3389/pore.2024.1611497
In the published article, there was an error in the Funding statement. It originally stated:
“The authors declare that this study received funding from Pfizer. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”
The Funding statement has now been removed.
In the published article, there was an error in the Conflict of interest Statement. It originally stated:
“Authors GR and ZA-T were employed by RxTarget Ltd.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The correct Conflict of interest statement appears below.
“GR and ZA-T are employees of RxTarget Ltd., which was a paid contractor to Pfizer in connection with the development of this manuscript and was responsible for data curation and statistical analysis. This study was sponsored by Pfizer. Medical writing support was provided by Zsófia Barcza at Syntesia Medical Communications Ltd. and was funded by Pfizer. The funder had the following involvement in the study: administrative support and review regarding study design, statistical analysis, and manuscript development.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: chronic myeloid leukemia, real-word evidence, tyrosine kinase inhibitors, treatment outcome, overall survival
Citation: Batar P, Alizadeh H, Rokszin G, Abonyi-Toth Z and Demeter J (2024) Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary. Pathol. Oncol. Res. 30:1611758. doi: 10.3389/pore.2024.1611758
Received: 06 March 2024; Accepted: 07 March 2024;
Published: 21 March 2024.
Approved by:
Pathology and Oncology Research Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Batar, Alizadeh, Rokszin, Abonyi-Toth and Demeter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peter Batar, pbatar@med.unideb.hu